一分钟看懂
这是一项关于肝细胞癌的不适用研究，登记的药物或干预包括FOLFOX4；Adebrelimab；Apatinib；Icaritin；Retlirafusp alfa；QL1706；Bevacizumab；HAIC；The original treatment regimen，当前状态为招募中。登记地点显示中国南京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
FOLFOX4；Adebrelimab；Apatinib；Icaritin；Retlirafusp alfa；QL1706；Bevacizumab；HAIC；The original treatment regimen · 不适用
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- China Pharmaceutical University Affiliated Nanjing Tianyinshan Hospital · 南京
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Age ≥18 years old, male or female
- 2. Hepatocellular carcinoma patients diagnosed by cytology or tissue puncture, or who meet clinical diagnostic criteria and cannot be treated with radical treatment (radical surgery, ablation, radiotherapy, etc.)
- 3. Clinical disease progression after first-line targeted combined immune system therapy (PD-1 or PD-L1 monoclonal antibody only)
- 4. Life expectancy exceeds 3 months
- 5. ECOG physical condition score 0\~1
- 6. Women of childbearing age must have a serum pregnancy study done within 7 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must consent to contraception within 24 weeks from the date of signing the informed consent to the last administration of the study drug
- 7. Before the first dose of the investigational drug, the laboratory test values met the following conditions: ①blood routine (no blood transfusion within 14 days before screening, no hematopoietic stimulating drug correction) : white blood cell count (WBC) ≥ 2.0 × 109/L; platelet (PLT) ≥ 60× 109/L; hemoglobin content (HGB) ≥ 8.0 g/dL; ② Liver function: aspartate transferase (AST) ≤ 2.5x ULN; alanine aminotransferase (ALT) ≤ 2.5 x ULN; Serum total bilirubin (TBIL) ≤ 1.5 x ULN (except Gilbert syndrome total bilirubin ≤ 3.0 mg/dL); ③ Renal function: serum creatinine ≤ 1.5 x ULN or creatinine clearance rate (CrCl) ≥ 50 mL/minute; ④ Coagulation function: international normalized ratio (INR) ≤ 1.5 x ULN, activated partial thromboplastin time (APTT) ≤ 1.5 x ULN (only for patients who are not currently receiving anticoagulant therapy, patients who are currently receiving anticoagulant therapy should receive a steady dose of anticoagulant therapy)
- 8. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with the follow-up
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06893887；登记信息更新于 2026-10-01；本站同步于 2026-10-08。